According to a large retrospective study co-led by Memorial Sloan Kettering Cancer Center (MSK) and published in the Journal of Clinical Oncology, PTCy is an acceptable alternative to CNI-based prophylaxis in MUD HCT recipients and superior for MMUD HCT. These results will help improve minority donor participation in the National Marrow Donor Program registry. Learn more: https://lnkd.in/eiCFK6mM
Memorial Sloan Kettering Cancer Center’s Post
More Relevant Posts
-
Great discussion with Maggie Shaw at AJMC - The American Journal of Managed Care at #COA2024! The Change Healthcare cyberattack impacted almost every part of our healthcare ecosystem and it will be months before we are “back to normal”. Interesting how many of our session topics: Cybersecurity or Revenue Cycle were so timely.
In this interview, Kathy Oubre, MS, CEO of Pontchartrain Cancer Center, is 1 of 6 cochairs for the 2024 Community Oncology Alliance Oncology Conference, and here she discusses how meeting content has incorporated ongoing coverage of the extremely disruptive cyberattack and how there is still so much work to be done. Watch now: https://lnkd.in/ewnADaFs #COA2024
-
-
Today we barely scratch the surface of precision oncology, relying mostly on single-gene or single-protein markers to guide therapy. Cancer's biological complexity demands greater sophistication. One might envision a future where we use molecular signatures, AI-driven analytics, and other innovations to personalize treatment--but can our healthcare system handle this level of complexity, and how can innovators prosper if the market becomes increasingly fragmented? One might alternatively envision a future where we create better therapeutics that can act broadly with only simple biomarker guidance--but will ignoring much of cancer's complexity inevitably limit their impact for many patients? What vision should we strive for, and what will it take to achieve it? This is just a taste of the rich discussion we plan to have at this year's Emerging Frontiers in Oncology with our esteemed speakers. My co-planners--Uciane Scarlett, Prashant Girinath, Luke Timmerman, Jeff Bockman, Martin Strebl-Bantillo--and I are excited for it! Hope to see you there.
Mark your calendars and register now for the 6th Annual Emerging Frontiers in Oncology Summit. This event, sponsored by Lumanity, is a catalyst for groundbreaking discoveries in the world of oncology. This year's theme is "The Future of Precision Oncology." All funds from registrations will support the Damon Runyon Cancer Research Foundation as part of the Luke Timmerman 2024 Traverse. For more information and to register, visit https://buff.ly/48Laryb #Oncology #Cancer #CancerResearch #EmergingFrontiers #DamonRunyon #LukeTimmerman #LumanitySpeaks
-
For #TrialTuesday, Sara Tolaney, MD, of Dana-Farber Cancer Institute, leads Alliance A012103 trial that compares the effect of pembrolizumab to observation in patients with triple-negative #breastcancer who had a pathologic complete response after chemotherapy plus pembrolizumab. To learn more about this trial, visit https://lnkd.in/gf_bQiqD #NCI #NCTN
-
-
In light of significant strides in cancer treatment and prevention, a diagnosis no longer carries the grim prognosis it once did. Join us at #SXSW2024 for our “Rebranding Cancer” panel where experts will delve into reshaping the perception of cancer from one of fear to a more accurate portrayal of the advancements in oncology. Learn more about our panel and download the Oncology Inflection here: https://bit.ly/3SPZBkd
-
I am happy to share that I presented my research at the Bossche Maamdaggen 2024 conference. My presentation, titled "Complete Response Rate, Survival Outcomes and Treatment Patterns in Patients Treated with First-Line Pertuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer: A SONABRE Study," highlighted significant findings in the treatment of HER2-positive metastatic breast cancer. #BosscheMaamdaggen2024 #MetastaticBreastCancer #HER2Positive #Pertuzumab #SONABRE
-
-
Learn how a retrospective chart review can provide clinical insights for future treatments in our whitepaper: A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non–Small Cell Lung Cancer. https://lnkd.in/evaRZpXG #OncologyResearch
-
-
Join Prof Janice Lu and Prof François Duhoux in their comprehensive analysis of the EMERALD study's subgroup findings. Understand the impact of elacestrant in ER+/HER2- breast cancer with ESR1 mutations. Discover its potential as a game-changing oral therapy in personalized breast cancer care. Discover these vital insights. 👇 For all SABCS 2023 videos, find the link in the comments! #MediMix #BreastCancerTreatment #OncologyResearch
-
A timely discussion with Narjust Florez M.D. about the ALINA trial - Ben Solomon International Association for the Study of Lung Cancer FDA https://lnkd.in/eP_mXM89 #NSCLC #LungCancer #OncoDaily #Oncology #ClinicalTrials
-
-
Timely detection plays a pivotal role in the survival of women battling ovarian cancer. However, advancements in diagnostics and therapeutics for this disease have been slow to materialize. The ongoing prexasertib clinical trial has the potential to be a game-changer in saving lives. #OvarianCancerAwareness #ClinicalTrials #HealthcareInnovation
Ovarian cancer is often diagnosed when it is already advanced, and treatment options are often limited. Investigators at the NCI Center for Cancer Research have identified a drug that could benefit a subset of people whose cancer has become drug-resistant. A clinical trial to evaluate the drug, prexasertib, is underway. Learn more about the trial: http://spr.ly/6045e8e9S #OvarianCancer #NationalCancerResearchMonth
-
-
Calidi Biotherapeutics (NYSE American: CLDI) presents promising Phase 1 and preclinical data at ASCO 2024, showcasing NeuroNova's progress and RTNova & CLD-201's potential in cancer treatment. A major milestone for the oncolytic virotherapy space. Register HERE for our our upcoming webinar to learn how CLDI is arming the immune system to kill cancer: https://ow.ly/G6Yr50S6Yke
-
